The report "Leukapheresis Market by Product (Devices, Filters, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) - Global Forecast to 2027", is projected to reach USD 98.5 Million by 2027 from USD 65.6 Million in 2022, at a CAGR of 8.5% between 2022 and 2027. The Leukopaks market is projected to reach USD 784.2 Million by 2027 from USD 146.9 Million in 2022, at a CAGR of 39.8% between 2022 and 2027. The major factors driving the medical image analysis market during the forecast period include the increasing incidence and prevalence of leukemia, and the high demand for leukopaks in clinical research. On the other hand, high cost of therapeutic leukapheresis and leukopaks are expected to restraint market growth. The industry trends include increasing number of collaborations among pharma and biotech companies and introduction of customizable cryopreserved leukopaks.
Browse 226 market data Tables and 76 Figures spread through 294 Pages and in-depth TOC on "Leukapheresis Market by Product (Devices, Filters, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) - Global Forecast to 2027"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/leukapheresis-market-20283148.html
In this report, the overall Leukapheresis Market is divided into two sub-markets, the Leukapheresis Products Market and the Leukopaks Market. The Leukapheresis Products Market is classified into four segments—type, application, end user, and region, and the Leukopaks Market is classified into four segments—type, indication, end user, and region.
Disposables segment to dominate the leukapheresis products market in 2021.
The disposables segment occupied a larger share of the Leukapheresis Products market in 2021, which can be attributed to the recurrent use of disposables during leukapheresis procedures, the increasing adoption of leukapheresis products for the collection of leukopaks and isolated PBMCs from leukopaks for research applications, and the increasing adoption of therapeutic leukapheresis procedures.
The mobilized leukopaks segment to occupy the largest share of the leukopaks market in 2021.
The mobilized leukopaks segment accounted for the largest share of the leukopaks market in 2021. This can be attributed to a large number of mononuclear cells (MNCs) in these leukopaks compared to non-mobilized leukopaks, which increases their utility in research applications.
By end user, blood component providers & blood centers segment to hold the largest share of the leukapheresis products market.
The blood component providers & blood centers segment accounted for the largest share of the leukapheresis market in 2021. The increasing number of blood donations, the growing demand for leukopaks for the development of CAR T therapy, and the increasing demand for blood components in cancer research are expected to drive this segment during the forecast period.
“North America to occupy the largest share of the leukapheresis market in 2021
The Leukapheresis market is segmented into four major regions, namely, North America, Europe, Asia Pacific (APAC), and the Rest of the World.
North America accounted for the largest share of the Leukapheresis market in 2021. The strong presence of a large number of players and a large number of ongoing CAR T-cell therapy clinical trials are driving the growth of the leukapheresis market in the North American region.
Asia Pacific was the fastest growing region, which can be attributed to the growing number of personalized medicine, regenerative medicine, cell therapy research activities, and increasing funding for CAR T-cell therapy research.
Key players in the leukapheresis products market include Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), and Miltenyi Biotec (Germany).
Some prominent players in the leukopaks market are Discovery Life Sciences (US), StemExpress, LLC (US), Charles River Laboratories International, Inc. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), and ZenBio (US)
These companies adopted strategies such as product launches, business expansions, agreements, partnerships, and acquisitions to strengthen their presence in the Leukapheresis market.
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441